Sao Paulo, January 28, 2015 -- Moody's América Latina has today downgraded Brasil Pharma's corporate family ratings to B3/B1.br from B1/Baa3.br. The B3 rating level has historically been associated with default frequencies of 6.4% and 21.2% over 1- and 3-year investment horizons, respectively. The outlook remains negative.

Vollständigen Artikel bei Moodys lesen